Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (52)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Johnson, E. M.
Right arrow Articles by Denning, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, E. M.
Right arrow Articles by Denning, D. W.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 45, 85-93
© 2000 The British Society for Antimicrobial Chemotherapy

Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection

Elizabeth M. Johnsona, Karen L. Oakleyb,c,{dagger}, Sarah A. Radforda,{ddagger}, Caroline B. Mooreb, Peter Warnc, David W. Warnocka,# and David W. Denningc,d,*

a Mycology Reference Laboratory, Public Health Laboratory Service, Bristol BS2 8EL; Departments of b Microbiology, and c Medicine, University of Manchester School of Medicine, Hope Hospital, Salford M6 8HD; d Department of Infectious Diseases and Tropical Medicine (Monsall Unit), Delaunays Road, North Manchester General Hospital, Manchester M8 6RB, UK

Amphotericin B has been the standard therapy for invasive aspergillosis since its introduction in 1957. It is only moderately effective. Many susceptibility tests have been used but little variation has been noted between strains. We have studied three strains of Aspergillus fumigatusand one of Aspergillus terreusin a neutropenic mouse model of invasive aspergillosis and attempted to correlate the variable efficacy in vivowith MICs generated by over 30 different susceptibility test formats. One strain of A. fumigatus(AF65) and the strain of A. terreus(AT49) were ‘resistant’ and the remaining two strains of A. fumigatus(AF210 and AF294) were ‘susceptible’ in vivo. Only AT49 had elevated MICs of amphotericin (MIC 2 mg/L) by 41 of 54 in vitrotesting systems. With each test format, including Etest, there was no distinction between MICs obtained for AF65, AF210 and AF294 (MICs 0.125–64 mg/L depending on the test). Thus despite extensive efforts we have been unable to correlate susceptible test results with in vivooutcome in A. fumigatusbut we have with A. terreus, with some test formats. This suggests that, at present, amphotericin B susceptibility testing of A. fumigatus is of limited clinical value and further work needs to be done to find testing systems that can identify the ‘resistance’ documented in vivo.

{dagger} Present address: Health and Safety Laboratory, Broad Lane, Sheffield S3 7HQ, UK;

{ddagger} Present address: Research Institute for the Care of the Elderly, St Martin's Hospital, Bath BA2 5RP, UK;

# Present address: Chief of the Mycotic Diseases Branch, Centers for Disease Control and Prevention, National Center for Infectious Diseases Division, 1600 Clifton Road NE, MES-C09, Atlanta GA 30333, USA

* Corresponding author. Tel: +44-161-720-2734; Fax: +44-161-720-2732.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Eukaryot CellHome page
L. E. Cowen and W. J. Steinbach
Stress, Drugs, and Evolution: the Role of Cellular Signaling in Fungal Drug Resistance
Eukaryot. Cell, May 1, 2008; 7(5): 747 - 764.
[Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
L. Alcazar-Fuoli, E. Mellado, G. Garcia-Effron, M. J. Buitrago, J. F. Lopez, J. O. Grimalt, J. M. Cuenca-Estrella, and J. L. Rodriguez-Tudela
Aspergillus fumigatus C-5 Sterol Desaturases Erg3A and Erg3B: Role in Sterol Biosynthesis and Antifungal Drug Susceptibility
Antimicrob. Agents Chemother., February 1, 2006; 50(2): 453 - 460.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
E. K. Manavathu, J. L. Cutright, and P. H. Chandrasekar
In Vivo Resistance of a Laboratory-Selected Aspergillus fumigatus Isolate to Amphotericin B
Antimicrob. Agents Chemother., January 1, 2005; 49(1): 428 - 430.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
P. A. Warn, A. Sharp, J. Guinea, and D. W. Denning
Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida
J. Antimicrob. Chemother., May 1, 2004; 53(5): 743 - 749.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
E. Dannaoui, O. Lortholary, and F. Dromer
In Vitro Evaluation of Double and Triple Combinations of Antifungal Drugs against Aspergillus fumigatus and Aspergillus terreus
Antimicrob. Agents Chemother., March 1, 2004; 48(3): 970 - 978.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
K. Takemoto, Y. Yamamoto, Y. Ueda, Y. Sumita, K. Yoshida, and Y. Niki
Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis
J. Antimicrob. Chemother., February 1, 2004; 53(2): 311 - 317.
[Abstract] [Full Text] [PDF]


Home page
J Med MicrobiolHome page
E. Dannaoui, J. Meletiadis, A.-M. Tortorano, F. Symoens, N. Nolard, M.-A. Viviani, M.-A. Piens, B. Lebeau, P. E. Verweij, and R. Grillot
Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients
J. Med. Microbiol., February 1, 2004; 53(2): 129 - 134.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
P. J. Paterson, S. Seaton, H. G. Prentice, and C. C. Kibbler
Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B
J. Antimicrob. Chemother., November 1, 2003; 52(5): 873 - 876.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
T. J. Wetter, K. C. Hazen, and J. E. Cutler
Modification of Rapid Susceptibility Assay for Antifungal Susceptibility Testing of Aspergillus fumigatus
J. Clin. Microbiol., September 1, 2003; 41(9): 4252 - 4258.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
P. A. Warn, G. Morrissey, J. Morrissey, and D. W. Denning
Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B
J. Antimicrob. Chemother., April 1, 2003; 51(4): 913 - 919.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
A. Espinel-Ingroff, V. Chaturvedi, A. Fothergill, and M. G. Rinaldi
Optimal Testing Conditions for Determining MICs and Minimum Fungicidal Concentrations of New and Established Antifungal Agents for Uncommon Molds: NCCLS Collaborative Study
J. Clin. Microbiol., October 1, 2002; 40(10): 3776 - 3781.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
A. Espinel-Ingroff, A. Fothergill, J. Peter, M. G. Rinaldi, and T. J. Walsh
Testing Conditions for Determination of Minimum Fungicidal Concentrations of New and Established Antifungal Agents for Aspergillus spp.: NCCLS Collaborative Study
J. Clin. Microbiol., September 1, 2002; 40(9): 3204 - 3208.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
J. Mosquera, A. Sharp, C. B. Moore, P. A. Warn, and D. W. Denning
In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp.
J. Antimicrob. Chemother., August 1, 2002; 50(2): 189 - 194.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
J. Meletiadis, J. W. Mouton, J. F. G. M. Meis, B. A. Bouman, and P. E. Verweij
Comparison of the Etest and the Sensititre Colorimetric Methods with the NCCLS Proposed Standard for Antifungal Susceptibility Testing of Aspergillus Species
J. Clin. Microbiol., August 1, 2002; 40(8): 2876 - 2885.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
M.-Y. S. Moosa, G. J. Alangaden, E. Manavathu, and P. H. Chandrasekar
Resistance to amphotericin B does not emerge during treatment for invasive aspergillosis
J. Antimicrob. Chemother., January 1, 2002; 49(1): 209 - 213.
[Abstract] [Full Text] [PDF]


Home page
Clin. Microbiol. Rev.Home page
J. H. Rex, M. A. Pfaller, T. J. Walsh, V. Chaturvedi, A. Espinel-Ingroff, M. A. Ghannoum, L. L. Gosey, F. C. Odds, M. G. Rinaldi, D. J. Sheehan, et al.
Antifungal Susceptibility Testing: Practical Aspects and Current Challenges
Clin. Microbiol. Rev., October 1, 2001; 14(4): 643 - 658.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
J. Mosquera, P. A. Warn, J. L. Rodriguez-Tudela, and D. W. Denning
Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazole
J. Antimicrob. Chemother., October 1, 2001; 48(4): 583 - 586.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
C. B. Moore, C. M. Walls, and D. W. Denning
In Vitro Activities of Terbinafine against Aspergillus Species in Comparison with Those of Itraconazole and Amphotericin B
Antimicrob. Agents Chemother., June 1, 2001; 45(6): 1882 - 1885.
[Abstract] [Full Text]


Home page
Antimicrob. Agents Chemother.Home page
J. Mosquera, P. A. Warn, J. Morrissey, C. B. Moore, C. Gil-Lamaignere, and D. W. Denning
Susceptibility Testing of Aspergillus flavus: Inoculum Dependence with Itraconazole and Lack of Correlation between Susceptibility to Amphotericin B In Vitro and Outcome In Vivo
Antimicrob. Agents Chemother., May 1, 2001; 45(5): 1456 - 1462.
[Abstract] [Full Text]


Home page
J. Clin. Microbiol.Home page
M. A. Pfaller, S. A. Messer, K. Mills, and A. Bolmström
In Vitro Susceptibility Testing of Filamentous Fungi: Comparison of Etest and Reference Microdilution Methods for Determining Itraconazole MICs
J. Clin. Microbiol., September 1, 2000; 38(9): 3359 - 3361.
[Abstract] [Full Text]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.